Skip to main content
Lyka Labs Ltd. logo

Lyka Labs Ltd. — Investor Relations & Filings

Ticker · LYKALABS ISIN · INE933A01014 LEI · 3358001RHQJBCTT1ER45 BSE.NS Manufacturing
Open in API
Filings indexed 1,203 across all filing types
Latest filing 2026-05-26 Regulatory Filings
Country IN India
Listing BSE.NS LYKALABS

About Lyka Labs Ltd.

https://www.lykalabs.com

Lyka Labs Ltd. specializes in the development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company maintains a diverse product portfolio spanning multiple therapeutic categories, including anti-infectives, dermatologicals, cardiovascular agents, and pain management. A significant area of expertise for the organization is lyophilization technology, enabling the production of high-quality injectable formulations. The company operates advanced manufacturing facilities designed to meet international quality standards, supporting its operations in both domestic and global markets. Its core activities encompass the production of various dosage forms such as tablets, capsules, ointments, and sterile injectables, with a particular focus on specialized segments like cephalosporins and critical care medications.

Recent filings

Filing Released Lang Actions
Annual Secretarial Compliance Report for the year ended 31.03.2026
Regulatory Filings Classification · 90% confidence The document is an Annual Secretarial Compliance Report issued by a Practicing Company Secretary pursuant to SEBI LODR Regulations, submitted to stock exchanges. It is neither an annual or interim financial report, nor a proxy or dividend notice, but rather a compliance certificate/filing. It constitutes a regulatory compliance document and falls under the general category of Regulatory Filings.
2026-05-26 English
As per the letter attached
Earnings Release Classification · 85% confidence The document is an official stock exchange notification under SEBI Listing Regulations (Reg. 30 and 33) announcing the outcome of a Board meeting held on May 25, 2026. It includes the approval of impairment, fixation of record date, AGM date, and—most materially—the audited financial results for the quarter and year ended March 31, 2026 along with the Independent Auditor’s Report. This is not a full Annual Report (10-K) nor merely a publication notice (RPA/RNS), but rather the company’s earnings release of its audited year-end results. Therefore, it best fits the Earnings Release category. FY 2026
2026-05-25 English
As per the letter attached
Regulatory Filings Classification · 75% confidence The document is a SEBI Listing Regulations disclosure (Regulation 30 and 33) filed with BSE and NSE titled “Outcome of the Board Meeting” dated 25 May 2026. It outlines board approvals (impairment of investment, audited financial results, record date, AGM date) and encloses the audited quarterly and full‐year financial results with the auditor’s report as annexures. It is not a full Annual Report (10‐K), nor a pure interim/quarterly report (IR), nor a simple report‐publication notice (RPA) because it attaches substantive financial statements and the auditor’s report. It is also not an earnings release (ER) or management discussion (MDA). As a generic regulatory announcement under Indian Listing Obligations, it best fits the fallback category “Regulatory Filings” (RNS).
2026-05-25 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 85% confidence The document is a Board meeting outcome notice filed under SEBI Listing Regulations (Reg 30/33) to stock exchanges, which includes the audited financial results (quarter and full year ended March 31, 2026) along with the Auditor’s Report, and also details other Board decisions (impairment, record date, AGM notice). It clearly encloses substantive financial statements accompanied by an independent audit opinion, not merely a brief press release. This aligns with our definition of an Interim/Quarterly Report (IR): a comprehensive financial report for a period shorter than a full fiscal year (here the quarter and year‐to‐date results) containing actual financial data and analysis. Thus, the correct classification is IR. FY 2026
2026-05-25 English
Lyka Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2026 ,inter alia, to consider and approve As per letter attached
Regulatory Filings Classification · 82% confidence The document is an intimation of a Board meeting under SEBI Listing Regulations to consider and approve audited financial results. It contains no actual financial data, management changes, or the results themselves, and is essentially a regulatory notice. It does not fit specific categories like Board/Management changes (no appointments), results release (no results detailed), or report publication (no report attached). Thus it falls into the fallback Regulatory Filings category (RNS).
2026-05-12 English
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details ....
Regulatory Filings Classification · 75% confidence The document is a compliance letter submitted to the Indian stock exchanges under SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144. It declares non-applicability of the SEBI fund-raising disclosure requirement and attaches an annexure. It is not an earnings release, capital market transaction announcement, nor a financial report itself, but rather a regulatory compliance filing. Therefore, it falls under the general “Regulatory Filings” category.
2026-04-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.